BGM0504 vs olatorepatide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1/GIP receptor (dual) · full Obesity pipeline

BGM0504

Developed by BrightGene Bio-Medical Technology and partners

Phase 3 in Obesitypeptide
Partial signal

NCT06973681 · Phase 2 · completed

This randomized, double-blind, placebo-controlled Phase 2 trial enrolled 120 adults with overweight or obesity across three weekly BGM0504 doses and placebo. The primary endpoint was percentage change in body weight from baseline to week 24. A company announcement reported placebo-adjusted mean weight reductions of 10.77% to 19.78% across the BGM0504 dose groups, meeting the primary endpoint. No power calculation or planned enrolment was available to show the trial was adequately powered, and the result is not posted on ClinicalTrials.gov.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: February 2027 · NCT07658560 (registry estimate)

Reported efficacy

Percentage change in body weight (Week 0 to Week 24): Placebo-adjusted LS-mean body weight reductions of 10.77% to 19.78% across BGM0504 dose groups (120 Chinese adults with obesity) (met)

Result source: NCT06973681

olatorepatide

Developed by Regeneron Pharmaceuticals under a licence from Hansoh Pharmaceutical Group

Phase 3 in Obesitypeptide
Reliable signal

NCT06839664 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial (n=604). The co-primary endpoints, percent weight change and the proportion achieving at least 5% weight loss at week 48, were both met: participants lost up to 19.3% of body weight and up to 97.2% achieved at least 5% weight loss, both significantly better than placebo.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: January 2028 · NCT07685808 (registry estimate)

Reported efficacy

Percent Change from Baseline in Body Weight (Baseline, week 48); Percentage of Participants Who Achieve weight loss≥ 5% from Baseline (Baseline, week 48): Co-primary endpoints met at Week 48: up to 19.3% mean weight loss with olatorepatide from baseline (dose range 5/10/15mg); up to 97.2% of participants achieved ≥5% weight loss, statistically significant vs placebo. (met)

Result source: NCT06839664

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBGM0504olatorepatide
Body weight, % change—Not posted · NCT06704581—Not posted · NCT06839664
Weight loss of 5% or more—Not posted · NCT06704581—Not posted · NCT06839664
Weight loss of 10% or more—Not posted · NCT06704581—Not posted · NCT06839664
Waist circumference, change (cm)—Not posted · NCT06704581—Not posted · NCT06839664

Body weight, % change

BGM0504
—Not posted · NCT06704581
olatorepatide
—Not posted · NCT06839664

Weight loss of 5% or more

BGM0504
—Not posted · NCT06704581
olatorepatide
—Not posted · NCT06839664

Weight loss of 10% or more

BGM0504
—Not posted · NCT06704581
olatorepatide
—Not posted · NCT06839664

Waist circumference, change (cm)

BGM0504
—Not posted · NCT06704581
olatorepatide
—Not posted · NCT06839664
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

BGM0504
Placebo-adjusted LS-mean body weight reductions of 10.77% to 19.78% across BGM0504 dose groups (120 Chinese adults with obesity) NCT06973681 · Phase 2 · design grade: moderate · publication or press release

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

olatorepatide

Weight 19.3% @ 48wk
percent change · % of baseline
No placebo or comparator arm
NCT06839664 · Phase 3 · sponsor-reported, not registry data
Weight Loss 5% 97.2% @ 48wk
responder rate · % of participants
No placebo or comparator arm
NCT06839664 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BGM0504's landscape · olatorepatide's landscape